The Outcomes of Concomitant Hypofractionated Simultaneous Integrated Boost Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin monotherapy for Newly Diagnosed Locally Advanced Cancer Cervix with Positive Lymph Nodes.

Résumé fourni par la source

Aim of the work: to evaluate outcome of Concomitant Hypofractionated Simultaneous Integrated Boost (SIB) Intensity-Modulated Radiotherapy (IMRT) Plus Concurrent Weekly Cisplatin monotherapy for Newly Diagnosed Locally Advanced Cancer Cervix with Positive LNs in elderly patients. Patients and methods: twenty-one patients were included diagnosed with locally advanced cancer cervix ≥ 65 years old with good performance status and adequate organ functions. Eligible patients received concomitant chemotherapy in form of cisplatin monotherapy (40 mg/m2) weekly, during radiotherapy treatment in form of External Beam Radiotherapy (EBRT) with SIB due to patients` refusal or inability to receive brachytherapy (BRT). Treatment toxicity, progression free survival (PFS) and overall survival (OS) were recorded and analyzed. Results: The median age reported was 70 years, (range: 65-76 years) and the median follow up period was 35 months (ranged from 18-47 months). The OS was 90.2% at 2 years and 76.8% at 3 years. The median time to progression was 27 months (ranged from11 – 46 months). The PFS was 75.6 % at 2 years and 63.5% at 3 years. Conclusion: in locally advanced cervical cancer, SIB-IMRT could be considered an effective and safe treatment alternative in elderly patients or unavailable brachytherapy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.